Drug intelligence / Profile preview

Vaxsafe IBD

Development stage: Unknown
Lead developer: Bioproperties
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

Vaxsafe IBD is a live freeze-dried egg-produced intermediate plus Infectious Bursal Disease (Gumboro) vaccine designed for broilers, layers, and breeders. It has proven efficacy against most Gumboro strains, including very virulent IBD (vvIBD). The vaccine strain does not immunosuppress birds and can immunize in the presence of relatively high maternal antibodies. It stimulates virus neutralizing antibody that protects from homologous challenge by classical IBD viruses including vvIBD virus. The vaccine is available in 1000 & 2000 dose vials and is administered via drinking water. It was first registered in 2004 with Registration #56537.

Brand names: Vaxsafe IBD

Beyond the preview

Go deeper on Vaxsafe IBD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxsafe IBD.

Explore the full profile